期刊文献+

雷替曲塞联合顺铂治疗进展期食管癌疗效观察 被引量:7

下载PDF
导出
摘要 目的:观察雷替曲塞联合化疗治疗进展期食管癌的疗效及不良反应。方法将进展期食管癌患者随机分为2组:试验组39例给予雷替曲塞联合顺铂方案化疗,对照组41例给予氟尿嘧啶、顺铂方案化疗。2组均以21 d为1个周期,进行2个周期的治疗。治疗2个周期后进行近期疗效、不良反应及生存质量评价。结果试验组与对照组总有效率分别为36%及32%,差异无统计学意义(P =0.527)。试验组中位生存期为34周,对照组为30周,差异有统计学意义(P =0.013)。试验组Ⅲ~Ⅳ度胃肠道反应、Ⅲ~Ⅳ白细胞抑制、心脏Ⅱ度损伤、Ⅱ~Ⅲ度黏膜炎、Ⅱ~Ⅲ度腹泻发生率均低于对照组(P 均﹤0.05)。肝肾功能损伤、血小板抑制、脱发发生率2组间比较差异无统计学意义(P 均﹥0.05)。试验组 Karnofsky 评分及体质量治疗后无明显下降(P 均﹥0.05),对照组 Karnofsk 评分及体质量治疗后均明显下降(P 均﹤0.05)。结论雷替曲塞联合顺铂治疗进展期食管癌疗效好,可延长生存期,减轻不良反应,提高生存质量,该方案值得在临床上推广应用。
出处 《现代中西医结合杂志》 CAS 2014年第27期2989-2990,2997,共3页 Modern Journal of Integrated Traditional Chinese and Western Medicine
  • 相关文献

参考文献9

  • 1陈万青.2004-2005年中国恶性肿瘤发病与死亡的估计[J].中华肿瘤杂志,2009,31(9):664-668. 被引量:136
  • 2Jemal A,Siegel R,Ward E,et al.Cancer statistics,2007[J].CA Cancer J Clin,2007,57(1):43-66.
  • 3Jemal A,Siegel R,Ward E,et al.Cancer statistics,2009[J].CA Cancer J Clin,2009,59(4):225-249.
  • 4Fukushima M,Fujioka A,Uchida J,et al.Thymidylate synthase(TS)and ribonucleotide reductase(RNR)may be involved in acquired resistance to 5-fluorouracil(5-FU)in human cancer xenografts in vivo[J].Eur J Cancer,2001,37(13):1681-1687.
  • 5Yun T,Han JY,Lee JS,et al.Phase II study of weekly paclitaxel and capecitabine in patients with metastatic or recurrent esophageal squamous cell carcinoma[J].BMC Cancer,2011,11:385.
  • 6Yamazaki K,Hironaka S,Boku N,et al.A retrospective study of second-line chemotherapy for unresectable or recurrent squamous cell carcinoma of the esophagus refractory to chemotherapy with 5-fluorouracil plus platinum[J].Int J Clin Oncol,2008,13(2):150-155.
  • 7张天泽,徐光炜.肿瘤学[M].2版.天津:天津科学技术出版社,2005:1090-1109.
  • 8Galetta D,Giotta F,Rosati G,et al.Carboplatin in combination with raltitrexed in recurrent and metastatic head and neck squamous cell carcinoma:A multicentre phase II study of the Gruppo Oncologico Dell'Italia Meridionale(G.O.I.M.)[J].Anticancer Res,2005,25(6C):4445-4449.
  • 9Ferrari VD,Amoroso V,Valcamonico F,et al.Epirubicin,cisplatin,and raltitrexed in patients with advanced gastric and hepatobiliary carcinoma:a phase II study[J].Am J Clin Oncol,2004,27(5):445-448.

二级参考文献7

  • 1全国肿瘤防治研究办公室,全国肿瘤登记中心,卫生部疾病预防控制局.中国肿瘤登记年报(2004).北京:中国协和医科大学出版社,2008:10.
  • 2中华人民共和国卫生部.全国第三次死因回顾抽样调查报告.北京:中国协和医科大学出版社,2008:10.
  • 3Verdecchia A, De Angelis R, Francisci S, et al. Methodology for estimation of cancer incidence, survival and prevalence in Italian regions. Tumori, 2007, 93:337-344.
  • 4Yang L, Parkin DM, Ferlay J, et al. Estimates of cancer incidence in China for 2000 and projections for 2005. Cancer Epidemiol Biomarkers Prev, 2005, 14:243-250.
  • 5陈万青,张思维.中国肿瘤登记的代表性研究[J].中国肿瘤,2008,17(10):832-835. 被引量:12
  • 6董志伟,乔友林,李连弟,陈育德,王润田,雷通海,饶克勤,王汝宽,赵平,游伟程,鲁凤珠,戴旭东,王国清,罗贤懋,周海城.中国癌症控制策略研究报告[J].中国肿瘤,2002,11(5):250-260. 被引量:350
  • 7鲁凤珠,张思维,陈永红,邹小农,李连弟.中国肿瘤登记情况调查结果初步分析[J].中国肿瘤,2004,13(3):134-141. 被引量:22

共引文献176

同被引文献66

  • 1岳顺,张大红,周磊磊.雷替曲塞联合多西他赛治疗晚期胃癌的临床疗效[J].肿瘤防治研究,2014,41(2):160-162. 被引量:21
  • 2王新强,程秀祯,王世伟,代培永,林祥来,杨怀泮.放疗联合PF方案同步治疗中晚期食管癌[J].中华放射肿瘤学杂志,2005,14(3):215-215. 被引量:52
  • 3Hagner N, Joerger M. Cancer chemotherapy:targeting folic acid synthesis[ J ]. Cancer Manag Res ,2010,19 (5) :293 - 301.
  • 4Van CE, Oliveirea J. ESMO Guidelines Working Group. Ad- vanced colorectal cancer: ESMO clinical recommendations for diagnosis, treatment and follow - up [ J ]. Ann Oncol, 2009,20(4) :61 -65.
  • 5Barni S, Ghidini A, Coinu A, et al. A systematic review of raltitrexed- based first -line chemotherapy in advanced colorectal cancer [ J ]. Anticancer Drugs, 2014, 25 ( 10 ) : 1122 - 1128.
  • 6Liu Y, Wu W, Hang W, et al. Rahitrexed - based chemo- therapy for advanced colorectal cancer[ J]. Clin Res Hepa- tol Gastroenterol,2014,38 (2) : 219 - 225.
  • 7Bozkurt O, Karaca H, Ciltas A, et al. Efficacy and safety of rahitrexed combinations with uracil - tegafur or mitomycin C as salvage treatment in advanced colorectal cancer patients: a multicenter study of anatolian society of medical oncology (ASMO) [ J ]. Asian Pac J Cancer Prey,2014,15 (4) : 1845 - 1849.
  • 8王佳蕾,李进,刘天舒,等.雷替曲塞或5-FU/CF联合奥沙利铂治疗局部晚期或复发转移性结直肠癌多中心、随机、对照Ⅲ期临床试验[C].北京:第十届全国临床肿瘤学大会暨2007年CSCO学术年会中国临床肿瘤学教育专辑,2007:335-340.
  • 9Kim GP, Sargent D J, Mahoney MR, et al. Phase III noninfe- riority trial comparing irinotecan with oxaliplatin, fluoroura-cil,and leucovorin in patients with advanced colorectal car- cinoma previously treated with fluorouracil: N9841 [ J ]. J Clin Oneo1,2009,27(17) :2848 - 2854.
  • 10Shen J, Wang H, Wei J, et al. Thymidylate synthase mRNA levels in plasma and tumor as potential predictive biomark- ers for raltitrexed sensitivity in gastric cancer [ J ]. Int J Cancer,2012,131 ( 6 ) :938 - 945.

引证文献7

二级引证文献60

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部